Arctoris is the world’s first fully automated drug discovery platform. Headquartered in Oxford, UK, we have a global presence across APAC, North America and EMEA.
We combine end-to-end automation of experiment design and execution with blockchain-secured data capture. We partner with biotech and pharma companies that want to bring their programs from idea to IND faster.
Arctoris is the next step in drug discovery evolution. Ulysses, the unique technology platform developed by Arctoris, enables the company’s clients and partners to conduct their R&D – from target validation via hit finding and hit-to-lead to lead optimization and beyond – significantly faster, and with considerably improved data quality and depth. With its robotics, Arctoris generates more than 100 times more datapoints per assay than industry standard, making critical information in cell and molecular biology as well as biochemistry/ biophysics available earlier, leading to higher success rates and an accelerated progression of programs towards the clinic.
Arctoris offers both fee-for-service and risk-share agreements in small molecule and biologics discovery, and is trusted by biotech and pharma companies in the US, UK, Germany, Australia, Korea, Hong Kong, and many other countries.